Synthesis and anti-Mycobacterium tuberculosis activity of vanadium complexes with N,N,O-donor ligands

Abstract

Oxovanadium(IV) and dioxovanadium(V) complexes with Schiff base derivatives have been prepared, characterized and their in vitro antibacterial activities were evaluated against the Mycobacterium tuberculosis H37Rv ATCC 27294. The studied Compounds include the free ligands 2-acetylpyidine-N(4)-phenyl-semicarbazone (Happs), 2-acetylpyridine-2-aminobenzoylhydrazone (Hapah), 2-acetylpyridine-benzoylhydrazone (Hapbh) and 2-acetylpyridine-furanoylhydrazone (Hapfh) and the complexes [VO2(apps)] (1), [VO2(apah)] (2), [VO(acac)(apbh)] (3), [VO2(apbh)] (4), [VO(acac)(apfh)] (5) and [VO2(apfh)] (6), which were prepared from bis(acetylacetonate)oxovanadium(IV) [VO(acac)(2)] in MeOH. The vanadium compounds show in general higher anti-M. tuberculosis activities than the free ligands. Some of the complexes presented MIC values better than those observed for some commonly used anti-M. tuberculosis agents, in the range 31.25 to 0.97 (mu g/mL).